SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BARALDI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.039
AS - Asia 1.444
EU - Europa 1.294
SA - Sud America 329
AF - Africa 45
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.159
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.976
CN - Cina 479
SG - Singapore 472
DE - Germania 280
BR - Brasile 277
IT - Italia 244
PL - Polonia 204
VN - Vietnam 122
HK - Hong Kong 120
TR - Turchia 120
GB - Regno Unito 117
UA - Ucraina 104
SE - Svezia 85
FI - Finlandia 69
RU - Federazione Russa 68
FR - Francia 37
CA - Canada 33
BE - Belgio 26
ID - Indonesia 26
IN - India 26
MX - Messico 24
ZA - Sudafrica 24
AR - Argentina 16
BD - Bangladesh 16
NL - Olanda 14
AT - Austria 13
ES - Italia 13
CL - Cile 10
EG - Egitto 10
IQ - Iraq 10
JP - Giappone 10
EC - Ecuador 7
CZ - Repubblica Ceca 6
PK - Pakistan 6
UZ - Uzbekistan 6
AU - Australia 5
CO - Colombia 5
TW - Taiwan 5
UY - Uruguay 5
PY - Paraguay 4
SA - Arabia Saudita 4
VE - Venezuela 4
BG - Bulgaria 3
IL - Israele 3
JO - Giordania 3
KE - Kenya 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
EU - Europa 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GL - Groenlandia 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
KH - Cambogia 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MC - Monaco 1
MK - Macedonia 1
MN - Mongolia 1
NA - Namibia 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.159
Salva come PNG Salva come JPEG
Città #
Dallas 770
Ashburn 402
Fairfield 360
Woodbridge 354
Singapore 285
Ann Arbor 207
Warsaw 200
Chandler 178
Beijing 174
Houston 168
Seattle 144
Wilmington 138
Santa Clara 137
Jacksonville 123
Cambridge 119
Hong Kong 117
Ferrara 108
Munich 74
Los Angeles 63
Izmir 58
New York 43
Shanghai 41
Milan 40
Nanjing 36
Princeton 34
Dong Ket 31
Boardman 27
Ho Chi Minh City 27
London 27
Brussels 26
Turku 25
San Diego 23
São Paulo 23
Hanoi 20
Bremen 19
Helsinki 19
Addison 18
Jakarta 18
Asnières-sur-Seine 14
Shenyang 14
Brooklyn 13
Chicago 13
Nanchang 13
Toronto 12
Jiaxing 11
Changsha 10
Frankfurt am Main 10
Hebei 10
Mexico City 10
Orem 10
Tokyo 10
Amsterdam 9
Council Bluffs 9
Des Moines 9
Moscow 9
Phoenix 9
Poplar 9
Querétaro 9
Stockholm 9
Cairo 8
Denver 8
Falls Church 8
Atlanta 7
Belo Horizonte 7
Brasília 7
Buffalo 7
Chennai 7
Hefei 7
Johannesburg 7
Mcallen 7
Montreal 7
Redwood City 7
Rio de Janeiro 7
San Francisco 7
Tianjin 7
Washington 7
Baghdad 6
Boston 6
Curitiba 6
Guangzhou 6
Montréal 6
Norwalk 6
Auburn Hills 5
Cape Town 5
Columbus 5
Guarulhos 5
Haiphong 5
Jinan 5
Kunming 5
Montevideo 5
Mumbai 5
Nuremberg 5
Salvador 5
Tashkent 5
The Dalles 5
Zhengzhou 5
Ankara 4
Bari 4
Brno 4
Cagliari 4
Totale 5.142
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 1.171
Design and Synthesis of New A2B Adenosine Receptor Antagonists 258
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 252
2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition 238
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 236
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 235
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 230
A3 adenosine receptor antagonists: History and future perspectives 228
7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation 222
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3’,4’,5’-Trimethoxyphenyl)-2-Aryl-1H-Imidazole 218
Design, synthesis and biological evaluation of 3-substituted-2-oxindole hybrid derivatives as novel anticancer agents 218
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 212
Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents 206
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 204
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 203
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 197
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 188
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 184
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 183
Synthesis and Biological Evaluation of Novel Allosteric Enhancers of the A1 Adenosine Receptor Based on 2-Amino-3-(4’-Chlorobenzoyl)-4-Substituted-5-Arylethynyl Thiophene 176
Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors 156
Synthesis and biological evaluation of alpha-bromoacryloylamido indolyl pyridinyl propenones as potent apoptotic inducers in human leukaemia cells 133
null 121
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 119
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 119
null 118
3-Aryl/Heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization 116
Adenosine Receptors in Colon Carcinoma Tissues and Colon Tumoral Cell Lines: Focus on the A3 Adenosine Subtype 110
Novel 1,3-Dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as Potent and Selective A2B Adenosine Receptor Antagonists 109
null 103
Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists. 100
null 96
null 90
Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors 89
Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists 89
null 84
Design, Synthesis, and Pharmacological Properties of New Heteroarylpyridine/Heteroarylpyrimidine Derivatives as CB2 Cannabinoid Receptor Partial Agonists 83
null 83
Synthesis and Biological Evaluation of Novel 2-Amino-3-Aroyl-4-Neopentyl-5-Substituted Thiophene Derivatives as Allosteric Enhancers of the A1 Adenosine Receptor 76
Totale 7.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.432
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.732
Totale 30.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021431 0 0 0 0 0 54 28 79 28 121 62 59
2021/2022441 26 25 34 25 36 34 23 24 27 40 36 111
2022/2023438 41 59 8 67 58 55 37 33 47 2 21 10
2023/2024273 19 21 13 9 32 61 8 34 2 6 4 64
2024/20251.063 30 50 92 47 102 96 73 63 144 74 149 143
2025/20262.263 313 308 784 361 442 55 0 0 0 0 0 0
Totale 7.253